Abstract
A new drug discovery strategy by inducing the degradation of oncoproteins through ubiquitin-proteasome system (UPS) has gained a lot of traction in the last decade (Verma et al. Mol Cell 77(3):446-460, 2020; Huang, Dixit. Cell Res 26:484, 2016). Multiple degrader platforms, such as IMiDs (Kronke et al. Science 343:301-305, 2014; Lu et al. Science 343:305-309; 2014), PROTAC (proteolysis targeting chimera) (Winter et al. Science 348:1376-1381, 2015), and molecular glues (Tan et al. Nature 446:640-645, 2007), have been approved or currently being developed in clinical trials. Compared to conventional drug inhibitors, degraders have a lot of advantages, such as catalytic mechanisms of action (MOA), no requirement of high-affinity ligands with targets, and potentially more sustained efficacy (Verma et al. Mol Cell 77(3):446-460, 2020; Huang, Dixit. Cell Res 26:484, 2016; Bondeson et al. Nat Chem Biol 11:611-617). Here, we describe protocols that measure intrinsic protein ubiquitination, degrader-induced target protein degradation, and cancer cell proliferation evaluation, as these protocols can help evaluate the potential of a drug target using a degrader platform.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
